Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Idera Pharmaceuticals to Present Preclinical Data of its Toll-Like Receptor-Targeted Compounds at AACR Meeting
April 23rd, 2008
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that preclinical data from its Toll-Like Receptor (TLR) programs will be presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA, April 12-16, 2008. Monday, April 14, 8:00AM-12:00PM (PDT): Immune Modulation 1 Session Abstract 2094 entitled "Preclinical antitumor studies of RNA-based agonists of TLR7 and 8" will be presented by Idera. In the study, TLR7 and 8 agonists were evaluated for antitumor activity in preclinical mice models. Abstract 2078 entitled "Antitumor activity of IMO-2055, an agonist of TLR9, in...
Source: Vaccine Weekly (2008-04-23)
|
